# Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT

> **NCT04127396** · PHASE4 · UNKNOWN · sponsor: **Beijing Ditan Hospital** · enrollment: 72 (estimated)

## Conditions studied

- Carcinoma, Hepatocellular
- Portal Vein Tumor Thrombus

## Interventions

- **DRUG:** Lenvatinib Pill
- **PROCEDURE:** Transarterial chemoembolization(TACE)
- **DRUG:** Sorafenib
- **PROCEDURE:** Transarterial chemoembolization(TACE)

## Key facts

- **NCT ID:** NCT04127396
- **Lead sponsor:** Beijing Ditan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-09-01
- **Primary completion:** 2021-08-01
- **Final completion:** 2021-12-01
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2021-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04127396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04127396, "Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04127396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*